1. Home
  2. OLOX vs DRMA Comparison

OLOX vs DRMA Comparison

Compare OLOX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Olenox Industries Inc. Common Stock

OLOX

Olenox Industries Inc. Common Stock

N/A

Current Price

$5.59

Market Cap

6.1M

ML Signal

N/A

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.19

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OLOX
DRMA
Founded
2007
2014
Country
United States
United States
Employees
N/A
9
Industry
RETAIL: Building Materials
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
5.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
OLOX
DRMA
Price
$5.59
$1.19
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
213.5K
53.1K
Earning Date
06-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$1,628.82
N/A
Revenue Next Year
N/A
$650.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.45
$0.59
52 Week High
$5.75
$7.33

Technical Indicators

Market Signals
Indicator
OLOX
DRMA
Relative Strength Index (RSI) 89.97 42.49
Support Level $0.58 $1.13
Resistance Level N/A $1.40
Average True Range (ATR) 0.37 0.08
MACD 0.53 -0.01
Stochastic Oscillator 96.98 4.35

Price Performance

Historical Comparison
OLOX
DRMA

About OLOX Olenox Industries Inc. Common Stock

Olenox Industries Inc is an industrial holding company focused on acquiring, operating, and scaling businesses that provide engineered solutions across industrial, energy, and infrastructure markets. Through its subsidiaries, it delivers high-quality modular and containerized systems designed for rapid deployment and long-term performance.

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

Share on Social Networks: